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Abstract 
Objective: Depression is associated with increased mortality in community samples.  The use of 
antidepressant medication may also increase mortality, however, it is still unclear whether taking 
antidepressants before or after a diagnosis of dementia influences survival.   
Design: Retrospective. 
Setting: A cohort with a diagnosis of Alzheimer’s disease (AD) from a large mental health and 
dementia care database in South London, linked to hospitalization and mortality data 
Participants: Mild dementia (mini-mental state examination ≥18/30) at the point of diagnosis. 
Measurements: We ascertained antidepressant prescription, either in the 6 months before or 
after dementia diagnosis, and used the HoNOS65+, a standard clinician-rated measure of patient 
wellbeing, to determine depression severity and other neuropsychiatric, physical health and 
functional difficulties. We conducted a survival analysis, adjusted for potential confounders and 
addressed possible confounding by indication through adjusting for a propensity score.  
Results: Of 5,473 patients with AD, 22.8% were prescribed an antidepressant in a one-year 
window around dementia diagnosis. Of these 2415 (44.1%) died in the follow-up period (mean 
(SD) 3.5 (2.4) years).  Prescription of an antidepressant, both before and after dementia 
diagnosis, was significantly associated with higher mortality after adjusting for a broad range of 
potential confounders including symptom severity, functional status and physical illness (hazard 
ratio 1.22; 95% CI 1.08-1.37 for prescription prior to dementia diagnosis; 95% CI 1.04-1.45 for 
prescription post dementia diagnosis). In stratified analyses risks remained significant in those 
without neuropsychiatric symptoms.    
Conclusion: The prescription of antidepressants around the time of dementia diagnosis may be a 
risk factor for mortality.  
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Introduction 
There is increasing recognition that psychiatric comorbidities are a common and distressing 
feature among people with Alzheimer’s disease (AD), 1 of which depression is one of the most 
prevalent and troubling. 2  Previous meta-analyses have concluded that depression is associated 
with increased risk of a person developing AD, potentially due to inflammatory processes, stress 
or reduced cognitive reserve.3  Furthermore, the prevalence of depression among people with AD 
may be as high as 80%4,5, and probably associated with higher mortality6 , greater medical 
comorbidity and poorer quality of life for the individual and careers 7.  
 
Antidepressant medications are a commonly used  treatment for depression in the general 
population 8 and  are also used in people with AD, 9 although there is uncertainty as to the 
benefits in people affected by dementia and/or AD.  Some trials support a beneficial effect 10-12 
but more recent studies report that antidepressants are not effective 13,14 as indicated by a 
Cochrane review.15  
 
In addition, there is a contentious debate about the potential association between antidepressant 
medication and higher mortality among people with AD.  In the general population, there have 
been mixed results for this association, including lower mortality 16,  no association 17 and higher 
mortality.18 However, information on people with AD remains sparse.  One previous study 
among people with dementia, found that antidepressant medication was associated with a 
significantly higher mortality risk of 36%,19 but another study found 18% lower mortality in 
people taking antidepressant medications for 3 years before an AD diagnosis.20  
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Given the high comorbidity of depression among people with AD, the common use of 
antidepressants, but paucity of studies on the relationship with mortality in this population, we 
aimed to investigate the association between the use of antidepressants and mortality in a large 
cohort of people with diagnosed AD.  
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Methods 
 
Data Source and Setting 
We obtained the data for this study using the South London and Maudsley NHS Foundation 
Trust (SLaM) Clinical Record Interactive Search (CRIS) application. CRIS has ethical approval 
(Oxford Research Ethics Committee C, reference 08/H0606/71+5) as an anonymised data source 
and, within a robust governance framework, it provides research access to anonymised copies of 
SLaM’s electronic health records.21,22 SLaM is one of Europe’s largest providers for dementia 
and mental health care and serves a geographic catchment of four South London boroughs 
(Lambeth, Lewisham, Southwark, and Croydon) with a population of over 1.2 million residents. 
Its electronic health records contain data on more than 270,000 cases across all age groups and 
mental health services, and secure linkages have been made to national data on hospitalisations 
(Hospital Episode Statistics; HES) and mortality. Data are extracted from routinely completed 
compulsory fields and supplemented by a range of natural language processing algorithms using 
General Architecture for Text Engineering (GATE) software to interrogate free text clinical 
records and correspondence.21,23 
 
Participants 
We used CRIS to identify patients who received a first diagnosis of dementia according to 
International Classification of Diseases, Tenth Revision (ICD-10) codes24 from SLaM outpatient 
services within between 1st January 2006 and 28th July 2016. To be included, patients needed to 
have a diagnosis of Alzheimer’s disease (etiher at first diagnosis or during the follow-up period), 
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and diagnosed with dementia in the mild stage defined as an Mini Mental State Examination 
(MMSE) score of 18 or higher at that time 25.  
 
Variables 
To distinguish longstanding antidepressant use from use associated with the diagnosis of 
dementia we defined two exposure groups. Patients were classified as prescribed antidepressants 
prior to dementia diagnosis if any antidepressant was mentioned in their case record in the 6 
months prior to dementia diagnosis. If the the antidepressant was continued after dementia 
diagnosis patients were also classified in this group. The second exposure group consisted of 
those prescribed an antidepressant in the 6 months after dementia diagnosis. Patients with AD 
who were not prescribed an  antidepressant in the one-year window around dementia diagnosis 
served as control group.  
 
Baseline covariates recorded were age, gender, ethnicity, marital status, a neighbourhood-level 
index of multiple deprivation26, and MMSE score closest to dementia diagnosis. To account for 
cerebrovascular co-morbidity we ascertained if an ICD-10 diagnosis of vascular (F01) or mixed-
type Alzheimer’s disease (F00.2) was mentioned in the follow-up period. General physical health 
and multi-morbidty was described through the ‘Physical illness and disability problems’ subscale 
of the Nation Outcome Scales (HoNOS65+) instrument. The HoNOS65+ is a standard measure 
of patient wellbeing used in UK mental health and dementia services and subscales are each 
rated 0 (no problem) to 4 (severe or very severe problem).27,28 In addition to the physical illness 
subscale, we also ascertained subscales relating to mental health symptoms and functional 
abilities. To facilitate interpretation, we dichotomised these to ‘minor or no problem’ (scores of 0 
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and 1) and ‘mild to severe problems’ (scores 2 to 4). Further, HoNOS65+ mental health problem 
scores were used to define subgroups of patients according to their neuropsychiatric symptom 
profile.   
 
Statistical analysis  
Analyses were conducted using STATA 13 software. Patients prescribed antidepressants were 
compared to the remainder with respect to other covariates. Patients were followed-up until their 
death or a census date on 10th December 2016. We used log-rank tests to compare survival 
between exposure groups and then applied Cox regression models to investigate associations 
between antidepressant prescription and survival. In order to reduce impact of confounding by 
indication, propensity scores were calculated. 29 These represent the probability of being treated 
with an antidepressant based on a regression model which included all the above mentioned 
covariates and we included the propensity score in a Cox model. 
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Results 
 
Population characteristics 
Among the 10,011 patients diagnosed with AD initially identified, of which 8,695 had an MMSE 
score recorded at diagnosis. 5,473 patients fulfilled inclusion criteria.  Of these, 2415 (44.1%) 
died in the follow-up period and mean (SD) follow-up time to death or the end of the observation 
period was 3.5 (2.4) years. 901 (16.5%) patients were prescribed an antidepressant prior to 
dementia diagnosis, of which 472 (8.6%) remained on the medication after diagnosis. 347 (6.3%) 
patients were prescribed an antidepressant after dementia diagnosis.  
Characteristics of antidepressant non-receivers and the two exposure groups are compared in 
Table 1. Antidepressant receivers were younger, more likely to be female, from a White ethnic 
background, and from more deprived areas. Those receiving antidepressants after dementia 
diagnosis had lower cognitive scores than those without or prior antidepressant prescription. 
Further patients prescribed antidepressants had worse scores on HONOS65+ subscales for 
agitated behaviour, non-accidental self injury, hallucinations or delusions, depressed mood, 
physical illness, and functional scales (activities of daily living, occupation and activities, social 
relationships). No signifcant difference in cerebrovascular co-morbidty was detected between 
groups.  
 
Predictors of mortality 
Adjusted and unadjusted multivariate Cox regression models are presented in Table 2. In models 
adjusted for demographics and cognition the following factors were assciated with higher 
mortality in the study cohort: higher age, being male, White ethnicity background, being from 
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more deprived areas and having a lower MMSE. In addition, poorer physical health and 
functional status, as well as the following neuropsychiatric symptoms were associated whith 
increased mortality:agitated behaviour, hallucinations or delusions, and depressed mood. Of 
note, two factors associated with antidepressant prescribing (lower age and female gender) were 
linked to better survival.  
 
Antidepressant receipt and survival 
A log rank test demonstrated significant differences in survival function between antidepressant 
non-receivers and those prescribed antidepressants before or after dementia diagnosis (chi2=14.0, 
p<0.01). Cox regression models also showed significant associations between antidepressant 
prescription and an increased risk for all-cause mortality. Associations did not seem to differ 
significantly between those prescribed antidepressant prior and after dementia diagnosis and 
remained significant after including a broad range of confounders into the models (Table 3). We 
created standard propensity scores from all available variables  and included those as covariates 
in a Cox regression model. In propensity score adjusted models both exposure groups differed in 
95% confidence intervals, but equal hazard ratios of 1.22 compared to non-rescription were 
detected.  
 
Stratified analyses according to neuropsychiatric symptom profiles 
We assessed the effect of antidepressant prescription in patients with depressed mood (n=483), 
with depressed mood and other co-morbid neuropsychiatric symptoms (agitated behaviour and/or 
psychotic symptoms; n=170), with agitation and/or psychosis, but no depressive symptoms 
(n=653), and in patients without any of the aforementioned neuropsychiatric problems (n=3,975) 
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(see Table 4). In patients with depressed mood antidepressant prescription prior to, but not after 
dementia diagnosis, was significantly associated with an increased mortality risk. In patients with 
agitated behaviour and/or psychotic symptoms antidepressant prescription did not lead to a 
significantly increased risk of death. Only in the group suffering from depressed mood and co-
morbid agitation/psychosis a trend towards increased mortality was detected in those prescribed 
an antidepressant after dementia diagnosis in a fully adjusted Cox regression model (HR 1.91; 
95% CI 0.89-4.11; p=0.08). Most notably, in the group without depression, agitation or 
psychosis, both antidepressant prescription prior and after dementia diagnosis resulted in an 
increased hazard for all-cause mortality.   
 
Differences in survival times 
In those who died in the follow-up period (n=2,415), mean (SD) survival time from dementia 
diagnosis to death was 3.3 (2.3) years. Mean (SD) survival time for patients not prescribed 
antidepressants was 3.4 (2.3) years, and for patients taking antidepressants prior to dementia 
diagnosis 3.1 (2.1) years and post dementia diagnosis 3.0 (2.3) years (p=0.01). This indicates a 
mean difference of 3-4 months of survival between antidepressant receivers and non-receivers.  
Survival time was significantly (p<0.01) shorter for patients with depressive symptoms (2.9 (SD 
2.3) years) than those presenting without depressed mood (3.4 (SD 2.3) years). In those who 
suffered from depressed mode and died in the follow-up period (n=266), no significant 
differences in survival time were detected between antidepressant receivers and non-receivers 
(p=0.77).   
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Discussion 
In this study of 5,473 patients with clinically diagnosed AD, we found that people who took 
antidepressant medications in the year encompassing the dementia diagnosis were more likely to 
die during the follow up period.  This association was similar in those with pre-dementia 
antidepressant prescritption and those receiving the medication after dementia diagnosis and 
remained robust after adjustment for potential confounders and in analyses including a 
propensity score representing the risk of being treated. Moreover, the presence of 
neuropsychiatric, functional, and physical health problems and socio-economic deprivation were 
associated with a higher mortality risk in this cohort of AD patients.  
 
Approximately 23% of the sample with AD were prescibed at least one antidepressant 
medication, and almost three quarters of those already before dementia diagnosis.  Compared to 
those not taking antidepressants, participants taking such medication had a higher presence of 
neuropsychiatric symptoms, had worse functioning according to HONOS65+ scores and worse 
physical health. Altogether, these findings suggest that participants taking antidepressant 
medications had a higher presence of risk factors for mortality, which may partly explain our 
findings.  However, the association of interest remained robust, although relatively small, after 
adjustment for these confounders.   
 
There are a number of potential mechanisms by which antidepressant medication may influence 
mortality in people with AD. First, antidepressant medications are associated with a higher risk 
of several medical conditions also associated with higher mortality risk; these include falls 
19,30,31, poor bone health 32, fractures 33, and potentially cardiovascular disease 34. Second, 
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antidpressants may interact with other medications taken by people affected by AD and increase 
the likelihood of adverse effects. For example, the use of some antidepressants could lead to a 
prolongation of QT intervals, especially if co-prescribed with other medications commonly used 
in people affected by AD, such as antipsychotics. 35 Finally, some antidepressants (like tricyclic 
medications) may have a role on on basal heart rate and heart rate variability36, two important 
factors for mortality.37  
 
Previous literature considering the relationship between antidepressant use and mortality among 
people with AD is equivocal and our findings add to a growing picture of a complex relationship.  
A large study including 20,050 participants affected by various types of dementia 20 reported that 
the use of antidepressant medications is associated with a significant lower risk of mortality.  
However, other large studies have reported an association with increased mortality. 19 Several 
reasons could explain these conflicting findings in the literature and our own data. First, factors 
as cognitive function, diagnostic criteria for AD, and the presence of diseases at higher risk of 
mortality could explain the differences. Second, the authors of the first study found that only a 
prolonged use of antidepressants (more than 3 years) was associated with a lower risk of 
mortality, whilst using antidepressants at the time of diagnosis or less than 3 years was not 
associated with any decreased risk. 20 Finally, our study had a considerably longer follow-up 
time than Enache et al. 20, who only observed their patients for two years after dementia 
diagnosis. It is conceivable that the hazardous effects of antidepressants only become apparent 
later in the dementia disease course.   
The findings of our study should be interpreted within its limitations. First, it is an observational 
study and so we cannot exclude that some potential confounders not considered in our analysis 
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could play a role in the association between antidepressants and mortality. Second, we did not 
have any information regarding the causes of mortality.Third, the type of antidepressant was not 
ascertained and so we are not able to conclude if a particular medication or class is responsible 
for the increased mortality found. Fourth, we assessed the use of antidepressants only in a 
window ranging from six months before to six months after first dementia diagnosis and this 
could introduce a bias in our results. Depressive symptoms, such as social withdrawal can be a 
prodromal feature of AD, 38 rather than representing clinical depression and we are unable to 
deliniate the clinical phenotype of our study sample. Fifth, we did not have sufficient information 
to adjust for level of education, although this is a factor partly reflected in the index of 
neighbourhood-level socio-economic status and a prospective studies have not found any 
association between educational level and survival in AD39. Sixth, co-morbidity was primarily 
ascertained through the HoNOS65+ ‘Physical illness and disability problems’ subscale, which 
although being widely used as routine measure of clinical outcome in dementia services in the 
UK, is a relatively brief measure. 
 
 
 
Conclusion 
Our findings suggest that antidepressants should be used cautiously in older people affected by 
AD, consistent with a longitudinal study showing that antidepressants are associated with a 
higher risk of adverse outcomes, including falls, hyponatraemia, cardiovascular and 
cerebrovascular conditions. 40 Since the benefits of antidepressant medications on mood in 
dementia may be limited, the prescribing clinician should carefully consider the risks and 
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benefits of doing so.  As this is a retrospective observational study, more solid evidence could be 
achieved through replicating these results in a prospective cohort study or a randomized 
controlled trial and future studies are needed to better elucidate the true role of antidepressants in 
AD. 
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Tables & Figures 
Table 1: Socio-demographic and clinical characteristics of the sample, by antidepressant status 
 
Risk factors Antidepressant non-
receipt 
(n=4,225) 
Antidepressant 
receipt prior 
(and post) 
dementia 
diagnosis 
(n=901) 
Antidepressant 
receipt post 
dementia 
diagnosis 
(n=347) 
P 
value* 
Socio-demographic status and cognitive function†   
   Mean age at dementia diagnosis (SD) 81.3 (7.3) 79.9 (8.7) 80.8 (8.4) <0.01 
Female gender (%) 62.0% 71.1% 70.3% <0.01 
Non-White ethnicity (%) 22.0% 19.1% 17.2% 0.03 
Married or cohabiting status (%) 38.0% 34.9% 33.4% 0.08 
Mean index of deprivation (SD) 25.2 (11.3) 26.7 (10.8) 26.4 (11.1) <0.01 
Mean MMSE score at diagnosis (SD) 22.8 (3.2) 23.0 (3.3) 22.3 (3.1) <0.01 
HoNOS65+ problem due to mental health symptoms (% with subscale scores 2-4)†  
Agitated behaviour 7.7% 16.2% 20.1% <0.01 
Non-accidental self-injury 0.6% 3.4% 2.1% <0.01 
Problem-drinking or drug taking 2.8% 2.6% 2.1% 0.84 
Hallucinations or delusions 7.7% 12.3% 13.0% <0.01 
Depressed mood 6.7% 33.6% 26.3% <0.01 
HoNOS65+ functional problem (% with subscale scores 2-4)†   
Activities of daily living 40.5% 49.4% 48.1% <0.01 
Living conditions 8.2% 7.5% 10.2% 0.37 
Occupational and recreational activities 21.6% 30.8% 32.1% <0.01 
Social relationships 9.2% 17.7% 19.8% <0.01 
HoNOS65+ ‘Physical illness or disability problems’ scale† <0.01 
0-1 (no or minor problem) 62.9%% 51.6% 52.2%  
2 (mild problem) 22.9%% 26.4% 26.3%  
3 (moderately severe problem) 12.4% 18.2% 18.0%  
4 (severe to very severe problem) 1.8% 3.8% 3.5%  
Cerebrovascular co-morbidity 35.1% 35.6% 39.5% 0.26 
Notes: * ANOVA, Kruskall-Wallis rank tesk or chi2 test ; † at the time of AD diagnosis 
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Table 2: Unadjusted and adjusted analyses of associations between covariates and mortality after Alzheimer’s 
disease diagnosis 
 
Covariate status at/around diagnosis Association with mortality – hazard ratio (95% CI) 
 Unadjusted Adjusted for demographics$ & 
MMSE 
Age (per year increment) † 1.08 (1.08-1.09)* 1.08 (1.08-1.09)* 
Female gender 0.82 (0.76-0.89)* 0.69 (0.64-0.75)* 
Non-white ethnicity 0.52 (0.45-0.58)* 0.61 (0.53-0.69)* 
Married or cohabiting status† 0.85 (0.78-0.93)* 0.97 (0.88-1.06) 
Deprivation score above sample mean† 1.09 (1.01-1.18)* 1.18 (1.08-1.28)* 
MMSE score (per unit increment) † 0.94 (0.93-0.95)* 0.95 (0.94-0.97)* 
HoNOS65+ problem due to mental health symptom † 
Agitated behaviour 1.31 (1.16-1.49)* 1.30 (1.14-1.47)* 
Non-accidental self-injury 1.08 (0.76-1.53) 1.12 (0.79-1.60) 
Problem-drinking or drug taking 1.03 (0.80-1.32) 1.21 (0.94-1.57) 
Hallucinations or delusions 1.32 (1.16-1.50)* 1.33 (1.16-1.52)* 
Depressed mood 1.01 (0.89-1.14) 1.17 (1.03-1.34)* 
HoNOS65+ functional problem † 
Activities of daily living (ADLs) 1.73 (1.60-1.88)* 1.49 (1.37-1.63)* 
Living conditions 1.61 (1.41-1.85)* 1.51 (1.31-1.74)* 
Occupational and recreational  activities 1.42 (1.30-1.56)* 1.30 (1.18-1.43)* 
Social relationships 1.14 (1.02-1.29)* 1.17 (1.03-1.32)* 
HoNOS65+ ‘Physical illness or disability 
problem’† 
1.76 (1.62-1.91)* 1.57 (1.44-1.71)* 
Cerebrovascular co-morbidity 1.07 (0.97-1.19) 1.08 (1.00-1.18) 
 
† at the time of AD diagnosis 
$ includes age, gender, ethnicity, marital status, deprivation score at dementia diagnosis 
* p<0.05  
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Table 3: Multivariate Cox regression analyses of association between receiving antidepressant treatment 
and mortality 
 
 
 
 
 
Antidepressant receipt 
prior (and post) dementia 
diagnosis 
Antidepressant receipt 
dementia diagnosis 
only  
Multivariate Cox regression models Hazard ratio (95% CI) Hazard ratio (95% 
CI) 
Unadjusted 1.15 (1.04-1.29)* 1.26 (1.08-1.46)* 
 
Adjusted for demographics$ and cognitive 
scores 
 
1.29 (1.16-1.44)* 
 
1.32 (1.13-1.55)* 
 
Adjusted for demographics, cognitive scores 
and all mental health  and functional problems 
HoNOS65+ subscales 
 
1.24 (1.10-1.39)* 
 
1.28 (1.09-1.51)* 
 
Adjusted for demographics, cognitive scores 
and hospitalization, HoNOS65+ physical 
illness subscale, and vascular co-morbidity  
 
1.22 (1.09-1.36)* 
 
1.26 (1.08-1.48)* 
 
Fully adjusted (for demographics, cognitive 
scores, and all HoNOS65+ subscales, and 
vascular co-morbidity) 
 
1.20 (1.06-1.35)* 
 
1.25 (1.06-1.48)* 
Adjusted using propensity score as co-variate 1.22 (1.08-1.37)* 1.22 (1.04-1.45)* 
 
 
$  includes age, gender, ethinicity, marital status, deprivation score at dementia diagnosis  
* p<0.05 
  
23 
 
Table 4: Adjusted hazard ratios (95% confidence intervals) of antidepressant use using multivariate Cox regression models 
 
  Patients with depressed mood± 
(n=483) 
 Patients with depressed mood and 
agitation/psychosis±  (n=170) 
 Patients with agitation/psychosis, but 
not depressed mood±  (n=653) 
 Patients without neuropsychiatric 
symptoms± 
(n=3,975) 
  N prescribed 
antidepressant 
(%) 
Model 
1 
Model 
2 
 N prescribed 
antidepressant 
(%) 
Model 
1 
Model 
2 
 N prescribed 
antidepressant 
(%) 
Model 
1 
Model 
2 
 N prescribed 
antidepressant 
(%) 
Model 
1 
Model 
2 
Antidepressant 
receipt prior (and 
post) dementia 
diagnosis 
 
 208 (43.1%) 1.42 
(1.03-
1.97)* 
1.56 
(1.12-
2.17)* 
 85 (50.0%) 0.85 
(0.51-
1.43) 
0.97 
(0.54-
1.74) 
 117 (17.9%) 1.24 
(0.94-
1.63) 
1.27 
(0.95-
1.69) 
 461 (11.6%) 1.28 
(1.10-
1.49)* 
1.20 
(1.03-
1.39)* 
Antidepressant 
receipt post 
dementia diagnosis 
 65 (13.5%) 1.13 
(0.70-
1.82) 
1.11 
(0.68-
1.83) 
 24 (14.1%) 1.28 
(0.67-
2.46) 
1.91 
(0.89-
4.11)# 
 64 (9.8%) 1.25 
(0.91-
1.72) 
1.31 
(0.94-
1.83) 
 185 (4.7%) 1.30 
(1.04-
1.61)* 
1.22 
(0.97-
1.53)# 
Model 1 = adjusted for demographics (includes age, gender, ethnicity, marital status, deprivation score at dementia diagnosis) and cognitive scores 
Model 2 = Fully adjusted (see Table 3) 
± using HoNOS65+ mental health problem subscales (a score of 2 or more represents a problem) 
* p<0.05 
# p<0.10 
